Drug intelligence / Profile preview

Oul Hiperimun Romvac

Development stage: Unknown
Lead developer: ROMVAC
Modality: Antibody-Based Therapeutics
Administration: Oral

Overview

**Oul Hiperimun Romvac** is an orally used Romanian dietary supplement derived from eggs of hens hyperimmunized with selected human-pathogen antigens. It contains a heterogeneous pool of pathogen-specific avian immunoglobulin Y antibodies and other egg-derived immunologically active proteins. Marketed through Imunoinstant and developed from Romvac technology, it is promoted as providing passive immune support against bacterial, viral, and fungal pathogens, including organisms described by the company as antimicrobial-resistant. It is a food supplement rather than a formally identified pharmaceutical medicine with an INN.

Brand names: Oul Hiperimun Romvac
Other names: Hiperimun RomvacHyperimmune EggOHR

Beyond the preview

Go deeper on Oul Hiperimun Romvac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oul Hiperimun Romvac.

Explore the full profile